WIM
IMCR icon

Waverton Investment Management’s Immunocore IMCR Stock Holding History

Waverton Investment Management’s Portfolio IMCR Stock Details IMCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-27,330
Closed -$1.02M – 82
2022
Q2 		$1.02M Sell
27,330
-10,000
-27% -$325K 0.04% 72
2022
Q1 		$1.12M Buy
+37,330
New +$942K 0.04% 70

Other funds holding IMCR

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return
GA
General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

Waverton Investment Management's IMCR Position: Q3 2022 in Review

Waverton Investment Management sold out of Immunocore (IMCR) in Q3 2022, closing a stake of 27,330 shares — an estimated $1.02M sold.

Waverton Investment Management first reported a position in IMCR in Q1 2022 and held it in 2 quarters. The position peaked at $1.12M in Q1 2022. 86 funds tracked by Wall St. Rank hold IMCR as of Q3 2022.

  • Waverton Investment Management reported no remaining Immunocore position as of Q3 2022 after selling out during the quarter.
  • Waverton Investment Management sold 27,330 Immunocore shares in Q3 2022, an estimated $1.02M.
  • Waverton Investment Management first reported a position in Immunocore in Q1 2022 and held it in 2 quarters.
  • Waverton Investment Management's Immunocore position peaked at $1.12M in Q1 2022.
  • 86 funds tracked by Wall St. Rank held Immunocore as of Q3 2022.

Based on Waverton Investment Management's 13F filing for Q3 2022, filed 19 Oct 2022.